Regeneron Pharmaceuticals (REGN) Q3 2025 earnings summary

Executive summary

• Q3 2025 revenues were $3.75B–$3.8B, with GAAP net income up 9% to $1.46B and diluted EPS up 18% to $13.62; non-GAAP EPS was $11.83, impacted by an $80M IPR&D charge.

• Dupixent global net sales reached $4.9B–$5.01B (up 26–28% YoY), with over 1.3M patients treated and strong U.S. growth.

• EYLEA HD U.S. net sales grew 10% YoY to $430.6M–$431M, partially offsetting a 41% drop in EYLEA U.S. sales due to biosimilar competition.

• Libtayo global net sales were $365M, up 24–26% YoY, with expanded approvals and market leadership in advanced CSCC.

• Robust pipeline progress with positive Phase III data in immunology, neurology, allergy, and rare diseases; FDA and EMA approvals for new indications.

Financial highlights

• Q3 2025 total revenues were $3.75B–$3.8B (flat to +1% YoY); net income was $1.3B–$1.46B (+9% YoY); diluted EPS was $13.62 (+18%).

• Gross margin on net product sales was 82–86%, reflecting product mix and higher manufacturing investments.

• Free cash flow for the first nine months of 2025 was $3.16B–$3.8B; cash and marketable securities totaled $16B–$18.7B at quarter end.

• Collaboration revenue increased 28% to $1.62B, driven by Dupixent profits; Regeneron's share of profits up 34% YoY.

• R&D expense was $1.48B in Q3 2025 (+16% YoY); SG&A was $658M (-8%).

Outlook and guidance

• 2025 guidance updated: GAAP R&D $5.68–$5.75B, non-GAAP R&D $5.10–$5.20B; capital expenditures $850M–$1.05B.

• Gross margin expected at ~82% (GAAP) and ~86% (non-GAAP); effective tax rate projected at ~14% (GAAP) and ~12% (non-GAAP).

• Management expects continued EYLEA pressure from biosimilars, but EYLEA HD and Dupixent growth to partially offset declines.

• Full reimbursement of Sanofi development balance expected by end of Q3 2026, boosting collaboration revenue.

• Key 2025 milestones include regulatory submissions, pivotal data readouts, and expansion into obesity and genetic medicines.